说明:双击或选中下面任意单词,将显示该词的音标、读音、翻译等;选中中文或多个词,将显示翻译。
您的位置:首页 -> 词典 -> BGC-823胃癌细胞
1)  BGC-823gastric cancer cell
BGC-823胃癌细胞
1.
Methods:At first,by high temperature and infection with NDV in vitro to probe into the alteration of morphology and proliferation of BGC-823gastric cancer cells by means of light microscopy and MTT assay.
目的:研究加热法及新城疫病毒(NDV)单独或联合体外诱导BGC-823胃癌细胞热休克蛋白70(HSP70)的表达及其意义。
2)  human gastric carcinoma cells BGC-823
人胃癌细胞BGC-823
1.
The mechanism of apoptosis in human gastric carcinoma cells BGC-823 induced with recombinant plasmid comprised Hemagglutinin-neuraminidase(HN) gene from newcastle disease virus;
新城疫病毒HN基因重组体对人胃癌细胞BGC-823凋亡作用机制研究
3)  Human gastric BGC-823 cell
人胃癌BGC-823细胞
1.
Incubation of human gastric BGC-823 cells with different concentration (15 μ g/ml, 30 μ g/ml and 45 μ g/ml) of EPA and DHA for 48h, then PKC β II were detected by flow cytometry,immuno cytochemistry and Western blot.
方法:将人胃癌BGC-823细胞分对照组、EPA药物组和DHA 药物组,EPA组和DHA组按15 μ g/ml、30 μ g/ml、45μ g/ml加药,肿瘤细胞培养48小时后,用流式细胞仪测定胃癌细胞PKC β II蛋白含量(鼠抗人PKC βⅡ抗体,1:50),以荧光指数(Flurorescene Index,FI)表示蛋白相对含量:FI= {样品蛋白表达的平均荧光强度/正常对照样品平均荧光强度} ×100%。
2.
Incubation of human gastric BGC-823 cells with different concentration (15 μ g/ml, 30 μ g/ml and 45 μ g/ml) of EPA and DHA for 48h,then NF- κ B p65 were detected by immuno cytochemistry, Western blot and TR-PCR.
方法:将人胃癌BGC-823细胞分对照组、 EPA药物组和DHA药物组,EPA组和DHA组按15 μg/ml、 30 μ g/ml和45 μg/ml药物浓度加药,肿瘤细胞加药继续培养48小时后,用SP-9000免疫细胞化学检测胃癌细胞NF- κ B p65蛋白分布(鼠抗人NF κ B p65单克隆抗体1:100), DAB显色,观察。
3.
When human gastric BGC-823 cells were treated by 15 μg/mL,30 μg/mL and 45 μg/mL of EPA and DHA after 48 hours, the techniques were used as follows: arachidonic acid (AA), EPA and DH.
本研究通过观察ω-3多不饱和脂肪酸制剂二十碳五烯酸 (cis-5,8,11,14,17-eicosapentaenoic aicd,EPA)和二十二碳六烯酸(cis-4,7,10,13,16,19-docosahexaenoic acid, DHA)对人胃癌BGC-823细胞膜ω-6多不饱和脂肪酸物质花生四烯酸(arachidonic acid,AA)和细胞内前列腺素E2 (PGE2)的影响,探讨ω-3多不饱和脂肪酸对人胃癌BGC- 823细胞的抑制作用机制。
4)  human gastric carcinoma cell line BGC-823
人胃癌BGC-823细胞
1.
Effects of activated carbon nanoparticles on human gastric carcinoma cell line BGC-823 in vitro
活性炭纳米粒子对人胃癌BGC-823细胞作用的体外实验研究
2.
Objective:To prepare the activated carbon nanoparticles(ACNP) of specific particle size and investigate the effects of ACNP on the human gastric carcinoma cell line BGC-823 in vitro.
目的:制备特定粒径范围的纳米活性炭(activated carbon nanoparticles,ACNP),探讨ACNP对人胃癌BGC-823细胞的作用及相关机制;同时,选择与ACNP在同一粒径范围的其他三种纳米颗粒(纳米SiO_2、纳米TiO_2、纳米ZnO),探讨不同化学组成的纳米颗粒对人胃癌BGC-823细胞的生物学效应及作用机制。
5)  grastic cancer cell line BGC-823
胃癌细胞株BGC-823
1.
Objective:To Investigate the inhibitory effect and mechanisis of combined treatment of the gastrin receptor antagonist proglumide and the selective COX-2 inhibitor celecoxib on cultured human grastic cancer cell line BGC-823 in vitro.
目的:探讨胃泌素受体拮抗剂丙谷胺和选择性还氧合酶-2抑制剂塞来昔布对体外培养的人胃癌细胞株BGC-823增殖抑制作用及其机制。
6)  BGC-823 gastric cancer cells
胃癌BGC-823细胞系
补充资料:14 Amino Acid Injection-823
药物名称:14氨基酸注射液-823

英文名:14 Amino Acid Injection-823

适应症: 主要用于手术前后、创伤、烧伤、骨折等分解代谢旺盛及低蛋白质血症等病人,由于肠道功能失调引起消化和吸收障碍的病人;由于厌食、拒食或限食等引起蛋白质摄取量不足所致的营养不良者;其他原因引起的慢性消耗性疾病病人。
用量用法:
静脉滴注常用量:1日250~500ml,严重消耗性疾病可增至1000ml。与高渗葡萄糖(25%以上)混匀后经中心静脉插管滴注,与5%~10%葡萄糖注射液混匀后经外周静脉缓慢滴注。滴注速度宜慢,每分钟以20~30滴为宜。
注意事项: 同11氨基酸注射注-833。
规格: 针剂:每瓶250ml、500ml。每100ml中含14氨基酸8.24g。



类别:营养药物
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条